Pharmacyclics Completes $57.1 Million Registered Direct Offering
June 17, 2011
Olshan’s client Pharmacyclics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company, announced that it completed a $57.1 million registered direct offering of its common stock. Olshan represented Pharmacyclics in this matter.